These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24162824)

  • 1. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.
    Bell MC; Jackson DJ
    Ann Allergy Asthma Immunol; 2012 May; 108(5):383-4. PubMed ID: 22541416
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.
    Paraskevopoulos G; Sifnaios E; Christodoulopoulos K; Mantopoulou F; Papakonstantis M; Sabaziotis D
    Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):52-5. PubMed ID: 23821833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
    Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
    J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.
    Jagdis A; Vadas P
    Ann Allergy Asthma Immunol; 2014 Jul; 113(1):115-6. PubMed ID: 24950847
    [No Abstract]   [Full Text] [Related]  

  • 6. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
    da Silva EN; Randall KL
    J Allergy Clin Immunol Pract; 2013; 1(6):687-8. PubMed ID: 24565720
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: A report of two cases.
    Prieto-García A; Álvarez-Perea A; Matito A; Sánchez-Muñoz L; Morgado JM; Escribano L; Álvarez-Twose I
    J Allergy Clin Immunol Pract; 2015; 3(3):456-8. PubMed ID: 25687289
    [No Abstract]   [Full Text] [Related]  

  • 8. Anaphylaxis to vapors of roasting chicken controlled by omalizumab.
    Barnig C; Hilger C; Muti D; Blaumeiser M; Purohit A; Hentges F; de Blay F
    J Investig Allergol Clin Immunol; 2012; 22(6):439-40. PubMed ID: 23101190
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.
    Molderings GJ; Raithel M; Kratz F; Azemar M; Haenisch B; Harzer S; Homann J
    Intern Med; 2011; 50(6):611-5. PubMed ID: 21422688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Systemic mastocytosis. Underestimated condition in patients with idiopathic anaphylaxis].
    Gülen T; Gottberg L; Dahlén B; Nilsson G; Hägglund H
    Lakartidningen; 2012 Feb 29-Mar 13; 109(9-10):474-7. PubMed ID: 22530411
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of omalizumab in the treatment of food allergy and anaphylaxis.
    Lieberman JA; Chehade M
    Curr Allergy Asthma Rep; 2013 Feb; 13(1):78-84. PubMed ID: 23065311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.
    Matito A; Blázquez-Goñi C; Morgado JM; Alvarez-Twose I; Mollejo M; Sánchez-Muñoz L; Escribano L
    Ann Allergy Asthma Immunol; 2013 Nov; 111(5):425-6. PubMed ID: 24125156
    [No Abstract]   [Full Text] [Related]  

  • 14. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
    Constantine GM; Bressler PB; Petroni D; Metcalfe DD; Carter MC
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1314-1316. PubMed ID: 30149096
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
    Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
    Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of idiopathic anaphylaxis in an adolescent.
    Pitt TJ; Cisneros N; Kalicinsky C; Becker AB
    J Allergy Clin Immunol; 2010 Aug; 126(2):415-6; author reply 416. PubMed ID: 20624653
    [No Abstract]   [Full Text] [Related]  

  • 17. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.
    Kontou-Fili K; Filis CI; Voulgari C; Panayiotidis PG
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):537-9. PubMed ID: 20568389
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase.
    Bilò MB; Corsi A; Agolini S; Tontini C; Antonicelli L
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):130-132. PubMed ID: 29577980
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
    Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
    Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
    [No Abstract]   [Full Text] [Related]  

  • 20. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema.
    Azofra J; Díaz C; Antépara I; Jaúregui I; Soriano A; Ferrer M
    Ann Allergy Asthma Immunol; 2015 May; 114(5):418-9.e1. PubMed ID: 25747788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.